國際貨幣基金組織晚宴籌集了超過 675,000 美元用於對抗骨髓瘤

國際骨髓瘤基金會 (IMF) 在其第 15 屆年度盛會上籌集了超過 675,000 美元，專門用於對抗骨髓瘤的研究和教育活動。該活動由名人和行業領袖參加，表彰了為骨髓瘤研究和患者支持做出貢獻的組織。這些資金將專門支持彼得·博伊爾研究基金、黑天鵝研究計畫以及解決骨髓瘤患者健康差異的計畫。

International Myeloma Foundation Gala Raises Over $675,000 for Myeloma Research and Education

國際骨髓瘤基金會晚會為骨髓瘤研究和教育籌集了超過 675,000 美元

The International Myeloma Foundation (IMF) held its 15th annual gala in New York City in April, raising over $675,000 for groundbreaking myeloma research and educational initiatives. The event, recognized as a testament to the collective efforts and unwavering dedication of the myeloma community, was a resounding success.

國際骨髓瘤基金會 (IMF) 於 4 月在紐約市舉辦了第 15 屆年度盛會，為突破性的骨髓瘤研究和教育計劃籌集了超過 675,000 美元。這項活動取得了巨大成功，被認為是骨髓瘤界集體努力和堅定奉獻的證明。

"This gala is a celebration of our shared purpose and determination to conquer myeloma," remarked Yelak Biru, President and CEO of the IMF. "We unite patients, caregivers, researchers, doctors, supporters, and industry partners, guided by our unwavering commitment to finding a cure."

國際貨幣基金組織總裁兼首席執行官耶拉克·比魯 (Yelak Biru) 表示：“這次盛會是對我們戰勝骨髓瘤的共同目標和決心的慶祝。” “我們將患者、護理人員、研究人員、醫生、支持者和行業合作夥伴團結起來，堅定不移地致力於尋找治療方法。”

Highlighting the significance of research funding, Biru emphasized that "science and research require financial support, without which finding a cure for myeloma remains an elusive goal." The gala's success brings the IMF closer to its aspirations of advancing myeloma research and accelerating the path towards a definitive cure.

Biru 在強調研究經費的重要性時強調，“科學研究需要財政支持，如果沒有財政支持，找到治療骨髓瘤的方法仍然是一個難以實現的目標。”此次盛會的成功使國際貨幣基金組織更接近其推動骨髓瘤研究和加速最終治癒之路的願望。

The event was graced by renowned actor and comedian Ray Romano, along with esteemed guest appearances by Tony Danza, Robert Klein, Patricia Heaton, and Alex Meneses. The evening served as a platform to honor the Peter Boyle Research Fund, established in memory of the actor who succumbed to myeloma, and the contributions it makes to advancing myeloma research.

著名演員兼喜劇演員雷·羅馬諾(Ray Romano) 以及托尼·丹扎(Tony Danza)、羅伯特·克萊因(Robert Klein)、帕特里夏·希頓(Patricia Heaton) 和亞歷克斯·梅內塞斯(Alex Meneses) 等受人尊敬的嘉賓出席了此次活動。當晚是向彼得·博伊爾研究基金致敬的平台，該基金是為了紀念這位死於骨髓瘤的演員及其對推進骨髓瘤研究所做的貢獻而設立的。

"We have made significant strides in myeloma through collaborative efforts between researchers, pharmaceutical companies, patients, and non-profit foundations," stated S. Vincent Rajkumar, MD, Chairman of the Board for the IMF. "The IMF's 15th Annual Gala celebrates these advancements and reinforces our unwavering commitment to ongoing research and patient support."

國際貨幣基金組織董事會主席、醫學博士 S. Vincent Rajkumar 表示：“透過研究人員、製藥公司、患者和非營利基金會之間的合作，我們在骨髓瘤治療方面取得了重大進展。” “國際貨幣基金組織第 15 屆年度晚會慶祝了這些進步，並強化了我們對持續研究和患者支持的堅定承諾。”

Several organizations were acknowledged for their invaluable contributions to myeloma research. The IMF Diversity, Equity, and Inclusion Award, recognizing efforts to address health disparities, was bestowed upon Johnson & Johnson. Tyrone Brewer, President of U.S. Hematology at Johnson & Johnson, expressed the company's dedication to ensuring equitable access to care and health outcomes regardless of individual circumstances.

一些組織因其對骨髓瘤研究的寶貴貢獻而受到認可。國際貨幣基金組織多元化、公平和包容獎授予強生公司，以表彰其為解決健康差距所做的努力。強生公司美國血液學總裁 Tyrone Brewer 表示，該公司致力於確保無論個人情況如何，都能公平地獲得護理和健康結果。

The Partner of the Year Award honored LatentView Analytics for its partnership with the IMF in streamlining the process from diagnosis to treatment, facilitating the timely initiation of therapy and improving patient outcomes. Rajan Sethuraman, CEO of LatentView, expressed gratitude for the recognition and highlighted the collaboration's positive impact on patient lives.

年度合作夥伴獎表彰 LatentView Analytics 與國際貨幣基金組織的合作，簡化了從診斷到治療的流程，促進及時開始治療並改善患者的治療效果。 LatentView 執行長 Rajan Sethuraman 對此認可表示感謝，並強調了此次合作對患者生活的正面影響。

The IMF Innovation Award recognized the contributions of Bristol Myers Squibb and 2seventy bio in developing Abecma (idecabtagene vicleucel), a CAR T-cell therapy that has expanded approval for patients with hard-to-treat myeloma. The EU and other regulatory authorities have followed suit, demonstrating the potential of CAR T-cell therapies in addressing this challenging disease.

國際貨幣基金組織創新獎表彰了百時美施貴寶和 2seventy bio 在開發 Abecma (idecabtagene vicleucel) 方面的貢獻，這是一種 CAR T 細胞療法，擴大了對難治性骨髓瘤患者的批准。歐盟和其他監管機構也紛紛效仿，展示了 CAR T 細胞療法在解決這個具有挑戰性的疾病方面的潛力。

Carvykti (ciltacabtagene autoleucel), a BCMA-targeting CAR T-cell therapy developed by Janssen and Legend Biotech, has also recently received expanded approval in the U.S. and EU as a second-line treatment for relapsed or refractory multiple myeloma. This regulatory decision broadens the treatment options available to patients with progressive disease.

Carvykti (ciltacabtagene autoleucel) 是楊森和傳奇生物科技開發的一種 BCMA 靶向 CAR T 細胞療法，最近也在美國和歐盟獲得了擴大批准，作為複發或難治性多發性骨髓瘤的二線治療。這項監管決定拓寬了疾病進展患者的治療選擇。

The IMF's 15th Annual Gala stands as a testament to the tireless efforts and unwavering support of individuals and organizations committed to conquering myeloma. The funds raised will fuel groundbreaking research, foster educational initiatives, and empower patients with the knowledge and resources necessary to navigate their myeloma journey. As the search for a cure continues, the IMF remains steadfast in its mission to improve the lives of those affected by myeloma.

國際貨幣基金組織第 15 屆年度晚會證明了致力於戰勝骨髓瘤的個人和組織的不懈努力和堅定支持。籌集的資金將推動突破性的研究，促進教育舉措，並為患者提供導航骨髓瘤之旅所需的知識和資源。隨著尋找治療方法的繼續，國際貨幣基金組織仍然堅定不移地履行其改善骨髓瘤患者生活的使命。